to view the video.
Dr. Neal Shore discusses the evolving interest in Alpha-Emitting Radionuclide Therapy over the past 20 years, which is due to advances in the targeted delivery of radionuclides as well as increased availability of many different alpha emitters. These developments have led to a number of clinical trials in this space, particularly with Radium-223, which is the only targeted alpha-emitter therapy currently approved for use on mCRPC patients.
There is no evidence that a resistance mechanism can develop to a targeted alpha therapy (TAT), so Dr. Shore addresses ways to link payloads of other diagnostic entities to TAT. He also explores TAT’s biological consequences, what we’ve learned from radium-223, the first-in class TAT, and combining TAT with immunotherapy treatment, DNA repair inhibitors and hormonal therapy to enhance therapeutic benefit for the patient.